Leng B, Basse F, Becq-Giraudon B, Brenez M, Carbon C, Casanova P, Poigny D A, Groussin P, Legendre P, Le Menn G, Marechal J M, Montete P, Petit J, Rey M, Schmitt B, Vallat C, Vedel M
Nouv Presse Med. 1982 Nov 18;11(46):3435-8.
In this cooperative trial, 181 patients with various urinary tract infections were treated by dibekacin, a new hemi-synthetic aminoglycoside. Clinical and bacteriological results confirm the efficacy of dibekacin in this indication. Local and systemic tolerance, and thus renal and cochleo-vestibular, were very satisfactory.
在这项合作试验中，181例患有各种尿路感染的患者接受了新的半合成氨基糖苷类药物地贝卡星的治疗。临床和细菌学结果证实了地贝卡星在该适应症中的疗效。局部和全身耐受性，以及肾脏和耳蜗前庭耐受性都非常令人满意。
